Literature DB >> 15855480

Changing patterns in the selection of viral mutations among patients receiving nucleoside and nucleotide drug combinations directed against human immunodeficiency virus type 1 reverse transcriptase.

Mark A Wainberg1, Bluma G Brenner, Dan Turner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15855480      PMCID： PMC1087622          DOI： 10.1128/AAC.49.5.1671-1678.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  35 in total

1.  Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase.

Authors:  Alan Winston; Anton Pozniak; Sundhiya Mandalia; Brian Gazzard; Deenan Pillay; Mark Nelson
Journal:  AIDS       Date:  2004-04-09       Impact factor: 4.177

2.  Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team).

Authors:  D Descamps; P Flandre; V Calvez; G Peytavin; V Meiffredy; G Collin; C Delaugerre; S Robert-Delmas; B Bazin; J P Aboulker; G Pialoux; F Raffi; F Brun-Vézinet
Journal:  JAMA       Date:  2000-01-12       Impact factor: 56.272

3.  Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.

Authors:  M H St Clair; J L Martin; G Tudor-Williams; M C Bach; C L Vavro; D M King; P Kellam; S D Kemp; B A Larder
Journal:  Science       Date:  1991-09-27       Impact factor: 47.728

4.  Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.

Authors:  S Staszewski; J Morales-Ramirez; K T Tashima; A Rachlis; D Skiest; J Stanford; R Stryker; P Johnson; D F Labriola; D Farina; D J Manion; N M Ruiz
Journal:  N Engl J Med       Date:  1999-12-16       Impact factor: 91.245

5.  Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.

Authors:  Joel E Gallant; Schlomo Staszewski; Anton L Pozniak; Edwin DeJesus; Jamal M A H Suleiman; Michael D Miller; Dion F Coakley; Biao Lu; John J Toole; Andrew K Cheng
Journal:  JAMA       Date:  2004-07-14       Impact factor: 56.272

6.  Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.

Authors:  Roy M Gulick; Heather J Ribaudo; Cecilia M Shikuma; Stephanie Lustgarten; Kathleen E Squires; William A Meyer; Edward P Acosta; Bruce R Schackman; Christopher D Pilcher; Robert L Murphy; William E Maher; Mallory D Witt; Richard C Reichman; Sally Snyder; Karin L Klingman; Daniel R Kuritzkes
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

7.  Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014).

Authors:  Asda Vibhagool; Pedro Cahn; Mauro Schechter; Fiona Smaill; Luis Soto-Ramirez; Giampiero Carosi; Maria Montroni; Cristina E Pharo; Jamie C Jordan; Nicola E Thomas; Gill Pearce
Journal:  Curr Med Res Opin       Date:  2004-07       Impact factor: 2.580

8.  Resistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase.

Authors:  D Zhang; A M Caliendo; J J Eron; K M DeVore; J C Kaplan; M S Hirsch; R T D'Aquila
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

9.  Role of purine nucleoside phosphorylase in interactions between 2',3'-dideoxyinosine and allopurinol, ganciclovir, or tenofovir.

Authors:  Adrian S Ray; Loren Olson; Arnold Fridland
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

10.  Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens.

Authors:  E R Lanier; N Givens; C Stone; P Griffin; D Gibb; S Walker; M Tisdale; D Irlbeck; M Underwood; M St Clair; M Ait-Khaled
Journal:  HIV Med       Date:  2004-11       Impact factor: 3.180
View more
  7 in total

1.  Drug resistance mutation profiles of the drug-naïve and first-line regimen-treated HIV-1-infected population of Suzhou, China.

Authors:  Tingting Li; Feng Qian; Ting Yuan; Weilu Xu; Li Zhu; Jinlong Huang; Haiyan Wang; Yueping Zhu; Yinling Wang; Xiaohong Li; Saihong Gu; Zhuqing Tan; Hui Chen; Xiangrong Luo; Wei Zhu; Wenjuan Lu; Ping Xu; Ming Li; Yuying Chen; Yong Gao; Rongge Yang; Chuanwu Zhu; Binlian Sun
Journal:  Virol Sin       Date:  2017-08-07       Impact factor: 4.327

2.  Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors.

Authors:  Nicolas Sluis-Cremer; Chih-Wei Sheen; Shannon Zelina; Pedro S Argoti Torres; Urvi M Parikh; John W Mellors
Journal:  Antimicrob Agents Chemother       Date:  2006-11-06       Impact factor: 5.191

3.  Estimating the individualized HIV-1 genetic barrier to resistance using a nelfinavir fitness landscape.

Authors:  Kristof Theys; Koen Deforche; Gertjan Beheydt; Yves Moreau; Kristel van Laethem; Philippe Lemey; Ricardo J Camacho; Soo-Yon Rhee; Robert W Shafer; Eric Van Wijngaerden; Anne-Mieke Vandamme
Journal:  BMC Bioinformatics       Date:  2010-08-03       Impact factor: 3.169

4.  Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine.

Authors:  Michel Ntemgwa; Mark A Wainberg; Maureen Oliveira; Daniela Moisi; Richard Lalonde; Valeria Micheli; Bluma G Brenner
Journal:  Antimicrob Agents Chemother       Date:  2007-08-27       Impact factor: 5.191

5.  Quantitative Detection of Nucleoside Analogues by Multi-enzyme Biosensors using Time-Resolved Kinetic Measurements.

Authors:  Pravin Muthu; Stefan Lutz
Journal:  ChemMedChem       Date:  2016-03-02       Impact factor: 3.466

6.  A synthetic HIV-1 subtype C backbone generates comparable PR and RT resistance profiles to a subtype B backbone in a recombinant virus assay.

Authors:  David Nauwelaers; Margriet Van Houtte; Bart Winters; Kim Steegen; Kurt Van Baelen; Ellen Chi; Mimi Zhou; Derek Steiner; Rachelle Bonesteel; Colin Aston; Lieven J Stuyver
Journal:  PLoS One       Date:  2011-05-24       Impact factor: 3.240

7.  Determination of Phenotypic Resistance Cutoffs From Routine Clinical Data.

Authors:  Alejandro Pironti; Hauke Walter; Nico Pfeifer; Elena Knops; Nadine Lübke; Joachim Büch; Simona Di Giambenedetto; Rolf Kaiser; Thomas Lengauer
Journal:  J Acquir Immune Defic Syndr       Date:  2017-04-15       Impact factor: 3.731
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.